Companies: 10,795·Total market cap: $144.5T
Denali Therapeutics Inc.

Denali Therapeutics Inc.

DNLINASDAQHealthcare● Active
$19.31
$-0.21(-1.08%)
Market Cap$3.1B
P/E Ratio—
52W High$23.77
52W Low$12.58
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Denali Therapeutics Inc. (DNLI) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · DNLI · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-2.88dnli eps ttm · dnli earnings per shareEarnings history
PE Ratio (TTM)—dnli pe ratio ttm · dnli price to earningsPE Ratio deep dive
Revenue (TTM)0.00dnli revenue ttm · dnli annual revenueFull revenue history
Dividend YieldNo Dividenddoes dnli pay dividends · dnli dividend yieldDividend history
Shares Outstanding175.5Mdnli shares outstanding · dnli floatShares outstanding history
Next EarningsAug 10, 2026Est.dnli earnings date · dnli next earningsEarnings history

Explore Denali Therapeutics Inc. Data

dnli stock data · financials
Market Cap$3.1Bdnli market cap · dnli valuation
Analyst Forecast$31 · Buy
DividendsNo Dividenddoes denali therapeutics inc. pay dividends · dnli dividend yield
Revenue—denali therapeutics inc. annual revenue · dnli revenue
EarningsEPS $-2.97-15.56%dnli earnings · dnli eps
PE Ratio—dnli pe ratio · dnli price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
denali therapeutics inc. revenue · dnli revenue 2025
FY 2025Net Income-$512.5M▼ 21.23% YoY
202320242025
denali therapeutics inc. net income · dnli profit 2025
FY 2025EPS$-2.97▼ 15.56% YoY
202320242025
dnli eps · denali therapeutics inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$508.0MEPS: $-2.88View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy18 analystsis dnli a buy · dnli analyst rating
Strong Buy
0
Buy
18
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$23.00Low
$19.31Current
$30.80Avg Target59.50% upside
$40.00High
dnli price target · dnli 12 month forecast

Total: 18 · Buy rate: 100.0%

The DNLI analyst consensus is Buy, based on ratings from 18 Wall Street analysts over the past 3 months. The average 12-month price target is $30.80, representing +59.50% upside from the current price of $19.31.

Stock Performance

Full History
1D-0.72%
1W+0.21%
1M-1.22%
3M-1.57%
YTD+17.38%
1Y+32.29%
5Y-73.36%

About Denali Therapeutics Inc.

CEORyan J. Watts
IPO DateDec 8, 2017
Employees443
CountryUS
Websitedenalitherapeutics.com

Denali Therapeutics Inc. a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2)…

BiotechnologyHealthcareNASDAQUS

what is denali therapeutics inc. · dnli stock overview · denali therapeutics inc. company profile · who is denali therapeutics inc. ceo · dnli NASDAQ · denali therapeutics inc. headquarters · denali therapeutics inc. business segments

About Stock Overview & Key Data

Denali Therapeutics Inc. (DNLI) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Dec 8, 2017. As of the latest trading session, DNLI stock price is $19.31, with a market capitalization of $3.1B. The stock has returned +32.29% over the past 12 months and +17.38% year-to-date.

According to 18 Wall Street analysts, the consensus rating for Denali Therapeutics Inc. stock is Buy, with an average 12-month price target of $30.80. In fiscal year 2025, Denali Therapeutics Inc. reported revenue of — and net income of -$512.5M. For detailed data — including Denali Therapeutics Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Denali Therapeutics Inc. (DNLI) stock price is $19.31. The stock is traded on NASDAQ under the ticker symbol DNLI. The 52-week range is $12.58 – $23.77.

DNLI stock priceDNLI quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice